The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
READ ARTICLE HIDE ARTICLE
By Jenni Spinner
Cour Pharmaceuticals, a biotechnology firm working on novel nanoparticles to treat immune disorders, has announced the US Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its CNP-201. The proof-of-concept study will test the safety and efficacy of the drug in a proof-of-concept (Phase I/II) study in patients suffering from an allergy to peanuts.
Jon Puisis (president, CEO, and co-founder of Cour) said, "This will be the first clinical trial with a first-in-class therapy to reprogram the immune system to stop the allergic response to peanuts. Our hope is the clinical trials will confirm that CNP-201 can help eliminate the potentially fatal health risks associated with patients who have a peanut allergy."
CNP-201 is a biodegradable nanoparticle that encapsulates purified peanut protein extract and is administered via intravenous infusion. The nanoparticles containing peanut allergens are consumed by immune-presenting cells; when the particles and allergens are presented by the immune-presenting cell, they trigger reprogramming of the cellular functions of the immune system, reducing and possibly eliminating the potential risk of severe allergic reactions.
Learn More from Outsourcing-pharma